← All trials
NCT06752759
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 16, 2024
- Primary completion
- Sep 30, 2026
- Completion date
- Sep 30, 2026
- First posted
- Dec 31, 2024
- Last posted
- Dec 31, 2024
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Maimonides Medical CenterLead sponsor
- Maimonides Medical CenterSponsor investigator
Drugs studied
Indications studied
- Anesthetics
- Anti-Inflammatory Agents, Non-Steroidal
- Central Nervous System Agents
- Depression
- Hypnotics and Sedatives
- Ketamine
- Midazolam
- Pharmacokinetics
- Psychotropic Drugs
- Tranquilizing Agents
- Anti-Anxiety Agents
- Peripheral Nervous System Agents
- Neurotransmitter Agents
- GABA Agents
- Sensory System Agents
- Analgesics, Non-Narcotic
- GABA Modulators
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.